AKT1 and acute myeloid leukemia: Studies demonstrated that miR34a over-expression profoundly decreased AKT phosphorylation level in multiple cancer types [82, 83], indicating the promising efficacy of miR-34a mimics in inhibiting both PD-L1 and AKT activity as an AML immunotherapy.